nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

18.11.2023 | Original Paper

Changes in neuroactive steroids, neurotrophins and immunological biomarkers after monotherapy 8-week rTMS treatment and their relationship with neurocognitive functions in depression

verfasst von: Muhammed Emin Boylu, Şenol Turan, Eray Metin Güler, Fatma Betül Boylu, Özge Kılıç, Abdurrahim Koçyiğit, İsmet Kırpınar

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Repetitive transcranial magnetic stimulation (rTMS) has proven effective in the treatment of major depression. The underlying mechanisms of action are still poorly understood. We aimed to evaluate the changes in the levels of neuroactive steroids, neurotrophins and immunological biomarkers before and after rTMS treatment and assess the relationship of this change between clinical response and cognitive functions after monotherapy rTMS treatment. Twenty-three patients with major depressive disorder (MDD) and 25 matched healthy controls were included in the study. The Hamilton Depression Rating Scale (HDRS), Trail Making Test A and B forms and Digit Span Test were administered. Biomarkers (BDNF, TNF-α, IL-1ß, NAS) were run in the peripheral blood at the end of the first month that rTMS was administered daily and at the end of the 2nd month when that rTMS was administered once a week. Appropriate conditions were provided so that the relevant biomarkers were not affected by the biorhythm. After rTMS monotherapy, an increase in BDNF and allopregnanolone, a decrease in TNF-α, IL-1ß, DHEA, and DHEA-S levels was found to be statistically significant. The scores on cognitive tests increased with the treatment. Positive significant correlations was found between BDNF levels and cognitive tests at the end of the first and second months. Our findings suggest that the effects of rTMS treatment may be related to the neuroendocrine, neurotrophin, and immunological mechanisms. rTMS treatment is found to have positive effects on cognitive functions in the short term.

Nur mit Berechtigung zugänglich

George, M.S., et al., Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport: An International Journal for the Rapid Communication of Research in Neuroscience, 1995.

Brunoni AR et al (2015) BDNF blood levels after non-invasive brain stimulation interventions in major depressive disorder: a systematic review and meta-analysis. World J Biol Psychiatry 16(2):114–122PubMed

Padberg F et al (2002) Plasma concentrations of neuroactive steroids before and after repetitive transcranial magnetic stimulation (rTMS) in major depression. Neuropsychopharmacology 27(5):874–878PubMed

Kendler KS, Thornton LM, Gardner CO (2000) Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the “kindling” hypothesis. Am J Psychiatry 157(8):1243–1251PubMed

Monroe SM, Harkness KL (2005) Life stress, the" kindling" hypothesis, and the recurrence of depression: considerations from a life stress perspective. Psychol Rev 112(2):417PubMed

van Broekhoven F, Verkes RJ (2003) Neurosteroids in depression: a review. Psychopharmacology 165(2):97–110PubMed

Romeo E et al (1998) Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 155(7):910–913PubMed

Uzunova V et al (2004) Chronic antidepressants reverse cerebrocortical allopregnanolone decline in the olfactory-bulbectomized rat. Eur J Pharmacol 486(1):31–34PubMed

Longone P et al (2008) The complex roles of neurosteroids in depression and anxiety disorders. Neurochem Int 52(4–5):596–601PubMed

10.

Naert G et al (2007) Neuroactive steroids modulate HPA axis activity and cerebral brain-derived neurotrophic factor (BDNF) protein levels in adult male rats. Psychoneuroendocrinology 32(8–10):1062–1078PubMed

11.

Martin J et al (2019) Weak correlations between serum and cerebrospinal fluid levels of estradiol, progesterone and testosterone in males. BMC Neurosci 20:1–6

12.

Schulz K, Korz V (2010) Hippocampal testosterone relates to reference memory performance and synaptic plasticity in male rats. Front Behav Neurosci 4:187PubMedPubMedCentral

13.

Russo-Neustadt A, Chen M (2005) Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des 11(12):1495–1510PubMed

14.

Egan MF et al (2003) The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 112(2):257–269PubMed

15.

Guilloux J-P et al (2012) Molecular evidence for BDNF-and GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry 17(11):1130–1142PubMed

16.

Dwivedi Y et al (2003) Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 60(8):804–815PubMed

17.

Zunszain, P.A., N. Hepgul, and C.M. Pariante, Inflammation and depression. Behavioral neurobiology of depression and its treatment, 2013: p. 135–151.

18.

Zhao X et al (2019) Repetitive transcranial magnetic stimulation increases serum brain-derived neurotrophic factor and decreases interleukin-1β and tumor necrosis factor-α in elderly patients with refractory depression. J Int Med Res 47(5):1848–1855PubMedPubMedCentral

19.

Yukimasa T et al (2006) High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. Pharmacopsychiatry 39(02):52–59PubMed

20.

Zanardini R et al (2006) Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. J Affect Disord 91(1):83–86PubMed

21.

Lang UE et al (2008) Acute prefrontal cortex transcranial magnetic stimulation in healthy volunteers: no effects on brain-derived neurotrophic factor (BDNF) concentrations in serum. J Affect Disord 107(1–3):255–258PubMed

22.

Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23(1):56PubMedPubMedCentral

23.

Akdemir A et al (1996) Hamilton depresyon derecelendirme ölçeği (HDDÖ)’nin geçerliliği-güvenirliliği ve klinikte kullanımı. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 4(4):251–259

24.

Lezak M Neuropsychological Assessment 3rd Edition New York: Oxford University Press.[Google Scholar]. 1995.

25.

Bosgelmez S et al (2015) Reliability and validity of the Turkish version of cognitive assessment interview (CAI-TR). Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 25(4):365–380

26.

Benton AL (1945) A visual retention test for clinical use. Arch Neurol Psychiatry 54(3):212–216PubMed

27.

Küçükdeveci AA et al (2013) The reliability and validity of the World Health Organization Disability Assessment Schedule (WHODAS-II) in stroke. Disabil Rehabil 35(3):214–220PubMed

28.

Johnson KA et al (2013) Prefrontal rTMS for treating depression: location and intensity results from the OPT-TMS multi-site clinical trial. Brain Stimul 6(2):108–117PubMed

29.

O’Reardon JP et al (2007) Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiat 62(11):1208–1216PubMed

30.

George MS et al (2010) Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry 67(5):507–516PubMed

31.

Wang H-N et al (2017) Clustered repetitive transcranial magnetic stimulation for the prevention of depressive relapse/recurrence: a randomized controlled trial. Transl Psychiatry 7(12):1–9

32.

Demiroz D et al. Neurotrophic Factor levels and cognitive functions before and after the repetitive transcranial magnetic stimulation in treatment resistant depression. Journal of the College of Physicians and Surgeons--pakistan: JCPSP, 2022. 32(3): p. 335–339.

33.

Uzunova V et al (1998) Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci 95(6):3239–3244PubMedPubMedCentral

34.

Ströhle A et al (1999) Concentrations of 3α-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiat 45(3):274–277PubMed

35.

Sripada RK et al (2013) Allopregnanolone elevations following pregnenolone administration are associated with enhanced activation of emotion regulation neurocircuits. Biol Psychiat 73(11):1045–1053PubMed

36.

Maayan R et al (2000) Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. Biol Psychiat 48(7):693–701PubMed

37.

Wolkowitz OM et al (1999) Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 156(4):646–649PubMed

38.

Maurice T, Roman FJ, Privat A (1996) Modulation by neurosteroids of the in vivo (+)-[3H] SKF-10,047 binding to σ1 receptors in the mouse forebrain. J Neurosci Res 46(6):734–743PubMed

39.

Morsink LF et al (2007) Associations between sex steroid hormone levels and depressive symptoms in elderly men and women: results from the Health ABC study. Psychoneuroendocrinology 32(8–10):874–883PubMed

40.

Turan Ş et al (2014) Effects of electroconvulsive therapy on plasma levels of neuroactive steroids in inpatients with major depression. Int J Psychiatry Clin Pract 18(4):261–264PubMed

41.

Schüle C et al (2003) Influence of sleep deprivation on neuroactive steroids in major depression. Neuropsychopharmacology 28(3):577–581PubMed

42.

Schüle C, Nothdurfter C, Rupprecht R (2014) The role of allopregnanolone in depression and anxiety. Prog Neurobiol 113:79–87PubMed

43.

Baghai TC et al (2005) Plasma concentrations of neuroactive steroids before and after electroconvulsive therapy in major depression. Neuropsychopharmacology 30(6):1181–1186PubMed

44.

See RE et al (2021) Assessment of multiple salivary biomarkers during repetitive transcranial magnetic stimulation (rTMS) treatment for major depression. Psychiatry Res 302:114053PubMed

45.

Barrett-Connor E et al (1999) Endogenous levels of dehydroepiandrosterone sulfate, but not other sex hormones, are associated with depressed mood in older women: the Rancho Bernardo Study. J Am Geriatr Soc 47(6):685–691PubMed

46.

Schweiger U et al (1999) Testosterone, gonadotropin, and cortisol secretion in male patients with major depression. Psychosom Med 61(3):292–296PubMed

47.

Shores MM et al (2005) Low testosterone levels predict incident depressive illness in older men: effects of age and medical morbidity. J Clin Psychiatry 66(1):10897

48.

Perry PJ et al (2002) Testosterone therapy in late-life major depression in males. J Clin Psychiatry 63(12):20810

49.

Seidman SN, Spatz E, Roose SP (2001) Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry 62(6):20806

50.

Baischer W et al (1995) Hypothalamic-pituitary-gonadal axis in depressed premenopausal women: elevated blood testosterone concentrations compared to normal controls. Psychoneuroendocrinology 20(5):553–559PubMed

51.

Weber B et al (2000) Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression. Psychoneuroendocrinology 25(8):765–771PubMed

52.

Maehata K et al. (2020) Hippocampal 7α-hydroxylated neurosteroids are raised by training and bolster remote spatial memory with increase of the spine densities. Iscience 23(10).

53.

Chen C-Y et al. (2018) Gender differences in the relationships among neurosteroid serum levels, cognitive function, and quality of life. Neuropsychiatric Disease and Treatment: 2389–2399.

54.

Akwa Y (2020) Steroids and Alzheimer’s disease: changes associated with pathology and therapeutic potential. Int J Mol Sci 21(13):4812PubMedPubMedCentral

55.

Brunoni AR, Lopes M, Fregni F (2008) A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 11(8):1169–1180PubMed

56.

Molendijk M et al (2014) Serum BDNF concentrations as peripheral manifestations of depression: evidence from a systematic review and meta-analyses on 179 associations (N= 9484). Mol Psychiatry 19(7):791–800PubMed

57.

Liu JJ et al (2020) Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. Mol Psychiatry 25(2):339–350PubMed

58.

Hannestad J, DellaGioia N, Bloch M (2011) The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36(12):2452–2459PubMedPubMedCentral

59.

Dahl J et al (2014) The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 45:77–86PubMed

60.

Perrin AJ, Pariante CM (2020) Endocrine and immune effects of non-convulsive neurostimulation in depression: a systematic review. Brain Behav Immun 87:910–920PubMed

61.

Kim TD et al (2019) Cognitive enhancement in neurological and psychiatric disorders using transcranial magnetic stimulation (TMS): a review of modalities, potential mechanisms and future implications. Exp Neurobiol 28(1):1PubMedPubMedCentral

62.

Vanderhasselt M-A et al (2006) The influence of rTMS over the left dorsolateral prefrontal cortex on Stroop task performance. Exp Brain Res 169(2):279–282PubMed

63.

Martis B et al (2003) Neurocognitive effects of repetitive transcranial magnetic stimulation in severe major depression. Clin Neurophysiol 114(6):1125–1132PubMed

64.

Myczkowski ML et al (2012) Effects of repetitive transcranial magnetic stimulation on clinical, social, and cognitive performance in postpartum depression. Neuropsychiatr Dis Treat 8:491PubMedPubMedCentral

65.

Bridge DJ, Cohen NJ, Voss JL (2017) Distinct hippocampal versus frontoparietal network contributions to retrieval and memory-guided exploration. J Cogn Neurosci 29(8):1324–1338PubMedPubMedCentral

66.

Sözeri-Varma G et al (2012) Relationship between serum BDNF levels and cognitive functions, cortisol levels in depressive disorder? Psychiatry Behav Sci 2(2):58–65

67.

Shimada H et al (2014) Depressive symptoms and cognitive performance in older adults. J Psychiatr Res 57:149–156PubMed

Titel: Changes in neuroactive steroids, neurotrophins and immunological biomarkers after monotherapy 8-week rTMS treatment and their relationship with neurocognitive functions in depression
verfasst von: Muhammed Emin Boylu
Şenol Turan
Eray Metin Güler
Fatma Betül Boylu
Özge Kılıç
Abdurrahim Koçyiğit
İsmet Kırpınar
Publikationsdatum: 18.11.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 4/2024
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-023-01704-9

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Changes in neuroactive steroids, neurotrophins and immunological biomarkers after monotherapy 8-week rTMS treatment and their relationship with neurocognitive functions in depression

Abstract

Neu im Fachgebiet Psychiatrie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Update Psychiatrie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Influence of noninvasive brain stimulation on connectivity and local activation: a combined tDCS and fMRI study

Long-term medication for ADHD (LMA) trial: 2-year prospective observational study in children and adolescents. Core symptoms, daily functioning, and comorbidity outcomes

A network meta-analysis of efficacy, acceptability, and tolerability of antipsychotics in treatment-resistant schizophrenia

Emotional distress and dysregulation as treatment targets to reduce suicide in psychosis: a scoping review

Optogenetic activation of the lateral habenulaD1R–ventral tegmental area circuit induces depression-like behavior in mice

Correction: Different autism measures targeting different severity levels in children with autism spectrum disorder

Neu im Fachgebiet Psychiatrie

Hörschwäche erhöht Demenzrisiko unabhängig von Beta-Amyloid

So wirken verschiedene Alkoholika auf den Blutdruck

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

ADHS-Medikation erhöht das kardiovaskuläre Risiko

Update Psychiatrie